1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

12 Jun 2020
Admin
News Article

Usfda Grants Orphan Drug Status To Mexiletine Hydrochloride Lupin

Pharma Major Lupin On Monday Said The Us Health Regulator Has Granted Orphan Drug Designation (Odd) To Mexiletine Hydrochloride For The Treatment Of Myotonic Disorders. The Mumbai-Based Company'S Drug Namuscula (Mexiletine Hydrochloride) Is The First And Only Licensed Product To Treat Myotonia In Adults With Non-Dystrophic Myotonic (Ndm) Disorders.The Company Has Already Inked Distribution Agreements With Three Companies To Make The Drug Commercially Available In Select European Countries."There Is A Serious Unmet Medical Need For The Management Of Symptoms In Patients With Myotonic Disorders. The Decision By The Usfda To Grant Orphan Drug Designation To Mexiletine Brings Us Closer To Providing A Licensed Treatment Option For Patients In The Us," Lupin Ceo Vinita Gupta Said.The Us Food And Drug Administration (Usfda) Grants Odd Status To Medicines Intended For The Treatment, Diagnosis Or Prevention Of Rare Diseases Or Disorders That Affect Fewer Than Two Lakh People In The Us.Myotonic Disorders Are A Group Of Heterogeneous, Inherited, Neuromuscular Disorders Characterised By A Shared Symptom Called Myotonia, Which Is An Inability To Relax A Contraction Of Skeletal Muscle.The Muscular Contraction Can Take Place While Doing Everyday Activities Like Shaking Someone'S Hand, Blinking, Walking Across A Street And Climbing Stairs.Mexiletine Hydrochloride Reduces Myotonia Symptoms, Resulting In A Significant Improvement In Patient Quality-Of-Life And Other Functional Outcomes.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!